Neurotensin and its receptors in the control of glucose homeostasis

Mazella, Jean; Béraud-Dufour, Sophie; Devader, Christelle; Massa, Fabienne; Coppola, Thierry

doi:10.3389/fendo.2012.00143

Cited by 41 publications

(30 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NTS is a 13 amino acid neuropeptide that is closely associated with numerous biological activities in the central nervous system and periphery [ 34 ]. Beside the opioid-independent analgesic system involved in the pathophysiology of various mental disorders, NTS affects food intake, glucose homeostasis, body temperature, behavior and cortisol secretion [ 34 , 35 ]. NTS is also known as an anti-apoptotic factor in a variety of cells [ 36 ].…”

Section: Discussionmentioning

confidence: 99%

Comparison of the global gene expression profiles in the bovine endometrium between summer and autumn

Sakumoto

Hayashi

Saito

et al. 2015

Journal of Reproduction and Development

View full text Add to dashboard Cite

Heat stress compromises fertility during summer in dairy and beef cows by causing nutritional, physiological and reproductive damages. To examine the difference in endometrial conditions in cows between summer and autumn, gene expression profiles were compared using a 15 K bovine oligo DNA microarray. The trial was conducted in the summer (early in September) and autumn (mid-November) seasons of two consecutive years (2013–2014) in Morioka, Japan. Endometrial samples were collected from the cows using a biopsy technique. The expressions of 268 genes were significantly higher in the endometrium collected in summer than those collected in autumn, whereas the expressions of 369 genes were lower (P<0.05 or lower). Messenger RNA expressions of glycoprotein 2 (GP2), neurotensin (NTS),E-cadherin (CDH1) and heat shock 105kDa/110kDa protein 1 (HSPH1) were validated by quantitative real-time PCR. Transcripts of GP2 and NTS were more abundant in the endometrium from summer than in the endometrium from autumn (P < 0.05). In contrast, the mRNA expressions of CDH1 were lower (P < 0.05) and those of HSPH1 tended to be low (P = 0.09) in the endometrium from summer. Immunohistochemical staining showed that GP2, NTS and HSPH1 were expressed in the endometrial epithelial or glandular epithelial cells. The serum concentrations of NTS collected from the cows in summer were higher than those collected from cows in autumn (P < 0.05). Collectively, the different gene expression profiles may contribute to functional differences in the endometrium between summer and autumn, and the increases in GP2 and NTS may have a relationship with the endometrial deficiency that causes infertility of cows in summer.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of the global gene expression profiles in the bovine endometrium between summer and autumn

Sakumoto

Hayashi

Saito

et al. 2015

Journal of Reproduction and Development

View full text Add to dashboard Cite

show abstract

“…In dogs, xenin‐25 has a dose‐dependent neurotensin‐like effect on gall bladder contractions, with non dose‐dependent effects on jejunum contractions (Figure ) . However, it has been suggested that the effects of xenin‐25 on the intestine may not be mediated entirely through interaction with neurotensin receptors, indicating the presence of other receptors that regulate xenin‐25 activity, as discussed earlier . More recently, the ability of xenin‐25 to stimulate gastrointestinal transit has been demonstrated to be absent following Roux‐en‐Y gastric bypass surgery, signifying the importance of the duodenum in this regard.…”

Section: Biological Activity Of Xenin‐25mentioning

confidence: 92%

Emerging therapeutic potential for xenin and related peptides in obesity and diabetes

Craig

Gault

Irwin

2018

Diabetes Metabolism Res

View full text Add to dashboard Cite

Xenin-25 is a 25-amino acid peptide hormone co-secreted from the same enteroendocrine K-cell as the incretin peptide glucose-dependent insulinotropic polypeptide. There is no known specific receptor for xenin-25, but studies suggest that at least some biological actions may be mediated through interaction with the neurotensin receptor. Original investigation into the physiological significance of xenin-25 focussed on effects related to gastrointestinal transit and satiety. However, xenin-25 has been demonstrated in pancreatic islets and recently shown to possess actions in relation to the regulation of insulin and glucagon secretion, as well as promoting beta-cell survival. Accordingly, the beneficial impact of xenin-25, and related analogues, has been assessed in animal models of diabetes-obesity. In addition, studies have demonstrated that metabolically active fragment peptides of xenin-25, particularly xenin-8, possess independent therapeutic promise for diabetes, as well as serving as bioactive components for the generation of multi-acting hybrid peptides with antidiabetic potential. This review focuses on continuing developments with xenin compounds in relation to new therapeutic approaches for diabetes-obesity.

show abstract

“…Therefore, the function or the dysfunction of sortilin may be responsible for hypercholesterolaemia and myocardial infarction as well as in neurodegenerative disorders (for a review, see Carlo et al ., ). Sortilin may be also involved in several other diseases including diabetes and obesity (Kaddai et al ., ; Mazella et al ., ), and cancer (Wilson et al ., ). Sortilin is known to be shedded at the cell surface by MMPs (Navarro et al ., ).…”

Section: Trek‐1 Channel and Depressionmentioning

confidence: 99%

Targeting two‐pore domain K⁺ channels TREK‐1 and TASK‐3 for the treatment of depression: a new therapeutic concept

Borsotto

Veyssière

Maati

et al. 2014

British J Pharmacology

View full text Add to dashboard Cite

Depression is a disease that is particularly frequent, affecting up to 20% of the population in Western countries. The origins of this pathology involve multiple genes as well as environmental and developmental factors leading to a disorder that remains difficult to treat. Several therapies for depression have been developed and these mainly target monoamine neurotransmitters. However, these treatments are not only associated with numerous adverse effects, but they are also ineffective for more than one-third of patients. Therefore, the need to develop new concepts to treat depression is crucial. Recently, studies using knockout mouse models have provided evidence for a crucial role of two members of the two-pore domain potassium channel (K2P) family, tandem P-domain weak inward rectifying K + (TWIK)-related K + channel 1 (TREK-1) and TWIK-related acid-sensitive K + channel 3 (TASK-3) in the pathophysiology of depression. It is believed that TREK-1 and TASK-3 antagonists could lead to the development of new antidepressants. Herein, we describe the discovery of spadin, a natural peptide released from the maturation of the neurotensin receptor-3 (also known as sortilin), which specifically blocks the activity of the TREK-1 channel and displays particular antidepressant properties, with a rapid onset of action and the absence of adverse effects. The development of such molecules may open a new era in the field of psychiatry. AbbreviationsBDNF, brain-derived neurotrophic factor; COP, coatomer protein; FST, forced swimming test; K2P, two-pore domain potassium channel; MDD, major depressive disorder; NSC, neural stem cell; NSF, novelty-suppressed feeding task; NTS3 receptor, neurotensin receptor 3 (also known as NTR3 and sortilin); REM, rapid eye movement; SSRI, selective 5-HT re-uptake inhibitor; TASK-3, TWIK-related acid-sensitive K + channel 3 (also known as K2P9.1); THPP, 6,7,pyrimidine; TREK-1, TWIK-related K + channel 1(also known as K2P2.1); TST, tail suspension test IntroductionDepression is a polygenic and highly complex psychiatric disorder that is currently a major burden on society. It is highly heterogeneous in presentation and frequently exhibits high comorbidity with other psychiatric and somatic deficits. Depression is highly prevalent. It is thought to be the fourth most common cause of a worldwide of reduction in disability-adjusted life years and is predicted to become the second by 2020 (Kessler et al., 2005). The economic burden of this disease is estimated to be $53 billion per year in the United States, and more than $100 billion in Europe. The treatments available for depression are suboptimal and still unsatisfactory; less than 50% of depressed patients when treated achieve full remission. The antidepressants (ADs) currently available still have tolerability issues such as insomnia, weight gain, nausea and sexual dysfunction, which commonly lead to treatment discontinuation. All current ADs also have a slow onset of action, which may take several weeks to months to produce a therapeutic resp...

show abstract

Neurotensin and its receptors in the control of glucose homeostasis

Cited by 41 publications

References 77 publications

Comparison of the global gene expression profiles in the bovine endometrium between summer and autumn

Comparison of the global gene expression profiles in the bovine endometrium between summer and autumn

Emerging therapeutic potential for xenin and related peptides in obesity and diabetes

Targeting two‐pore domain K⁺ channels TREK‐1 and TASK‐3 for the treatment of depression: a new therapeutic concept

Contact Info

Product

Resources

About

Neurotensin and its receptors in the control of glucose homeostasis

Cited by 41 publications

References 77 publications

Comparison of the global gene expression profiles in the bovine endometrium between summer and autumn

Comparison of the global gene expression profiles in the bovine endometrium between summer and autumn

Emerging therapeutic potential for xenin and related peptides in obesity and diabetes

Targeting two‐pore domain K+ channels TREK‐1 and TASK‐3 for the treatment of depression: a new therapeutic concept

Contact Info

Product

Resources

About

Targeting two‐pore domain K⁺ channels TREK‐1 and TASK‐3 for the treatment of depression: a new therapeutic concept